Torii Pharmaceutical Co Ltd
TSE:4551
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Torii Pharmaceutical Co Ltd
Cash from Operating Activities
Torii Pharmaceutical Co Ltd
Cash from Operating Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Torii Pharmaceutical Co Ltd
TSE:4551
|
Cash from Operating Activities
¥3.2B
|
CAGR 3-Years
9%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
4%
|
|
|
Takeda Pharmaceutical Co Ltd
TSE:4502
|
Cash from Operating Activities
¥1.2T
|
CAGR 3-Years
4%
|
CAGR 5-Years
8%
|
CAGR 10-Years
19%
|
|
|
Daiichi Sankyo Co Ltd
TSE:4568
|
Cash from Operating Activities
¥123.9B
|
CAGR 3-Years
1%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-1%
|
|
|
Otsuka Holdings Co Ltd
TSE:4578
|
Cash from Operating Activities
¥403.6B
|
CAGR 3-Years
24%
|
CAGR 5-Years
12%
|
CAGR 10-Years
5%
|
|
|
Chugai Pharmaceutical Co Ltd
TSE:4519
|
Cash from Operating Activities
¥386.3B
|
CAGR 3-Years
17%
|
CAGR 5-Years
14%
|
CAGR 10-Years
N/A
|
|
|
Astellas Pharma Inc
TSE:4503
|
Cash from Operating Activities
¥457.8B
|
CAGR 3-Years
21%
|
CAGR 5-Years
11%
|
CAGR 10-Years
8%
|
|
Torii Pharmaceutical Co Ltd
Glance View
Torii Pharmaceutical Co., Ltd. engages in the manufacturing and marketing of pharmaceutical products. The company is headquartered in Chuo-Ku, Tokyo-To and currently employs 560 full-time employees. The company went IPO on 2013-10-01. The Company’s main product categories include oral pruritus improving agents, proteolytic enzyme inhibitors, hyperkalemia improving agents, topical adrenocortical hormones, allergen immunotherapy for cedar pollinosis, allergen immunotherapy for mite allergy, active viable bacterial preparations, uterine contraction inhibitors in premature birth and others. The Company’s main products include Remitch, Riona tablets, Keixalate, Yulinome tablets, Antebate, Locoid, Zefnate, Sida Torengi pollen sublingual solution, Miticure mite sublingual tablet, Biosley, Magcent and others.
See Also
What is Torii Pharmaceutical Co Ltd's Cash from Operating Activities?
Cash from Operating Activities
3.2B
JPY
Based on the financial report for Jun 30, 2025, Torii Pharmaceutical Co Ltd's Cash from Operating Activities amounts to 3.2B JPY.
What is Torii Pharmaceutical Co Ltd's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 10Y
4%
Over the last year, the Cash from Operating Activities growth was 152%. The average annual Cash from Operating Activities growth rates for Torii Pharmaceutical Co Ltd have been 9% over the past three years , and 4% over the past ten years .
